Lausanne, (Switzerland), Ghent, Brussels and Antwerp, (Belgium), 05.16.2017: Genohm and Pathomation agreed today to integrate their products and provide a single homogenous end-user experience in order to meet the needs of customers in the field of Pathology.
Genohm’s flagship platform, SLims, is a software solution that is used in many biobanks for managing specimen collections. Pathomation has developed PMA.core, a solution for decentral access to various digital pathology platforms.
Collections of human biological materials (Biobanks) together with associated clinical data are key resources in investigating genetic and environmental factors underlying (multifactorial) disease, improve the diagnosis and treatment and ultimately prevent or mitigate the disease. Translational biomedical research in particular is based on large collections of high quality samples together with large sets of well documented, up-to-date epidemiological, clinical, molecular information from large numbers of patients and controls.
Such collections are of the highest importance in both investigator-driven and sponsored clinical trials. Biobanks are therefore considered to be essential for the advancement of research and development in the life sciences.
Both SLims and PMA.core software solutions are currently rolled out at the Vrije Universiteit Brussel in Jette, Belgium. The PMA.core software is used there to manage and visualize content from the Diabetes Biobank.
Further integration of the two software environments provides a smoother end-user experience and allows optimization of both processing and analytical data- and workflows. Genohm has performed the necessary adaptations to SLims in order to run PMA.core from within the SLims user interface.
This cooperation allows both companies to approach potential customers with a full end-to-end solution for managing both specimens and their digital scans, from a single integrated interface.
Genohm’s history starts in 2002 as a spin-off of the University of Ghent, Belgium. Launched as a 2 person bio-informatics shop, the company has kept building up an extensive bio-informatics expertise within the life sciences R&D world. In 2010, Genohm released SLims, a digital platform providing laboratories with an integrated LIMS + ELN environment to enter the lab informatics market.
In 2011, Genohm opened its new HQ at the EPFL Innovation Park in Lausanne, Switzerland and in 2016 a US branch in Durham, NC. Today Genohm serves a growing set of customers in Europe, the Middle East and the US.
Genohm is ISO 9001 certified.
SLims is a digital platform used for managing all information in a laboratory. It is an all-in-one complete package which allows customers to track samples, interact with lab equipment and offers full data lifecycle management. SLims provides laboratories with one integrated Laboratory Information Management System (LIMS) + Electronic Lab Notebook (ELN) environment that tracks data and samples from the original sample shipment down to the result from lab machines and in-silico analysis pipelines.
The platform provides an environment to support the increasing complexity of handling, sharing, analyzing and understanding data generated by any laboratory active in research, next-generation sequencing, diagnostics or biobanking. Currently used by over 60 labs worldwide, from small research facilities up to large governmental institutions, SLims helps scientists manage millions of samples and results.
SLims supports 21 CFR part 11 compliance
About the Brussels Free University (VUB):
VUB is the offshoot of the French-speaking Université Libre de Bruxelles (ULB) that was founded in 1834 by a Brussels lawyer with Flemish origins, Pierre-Théodore Verhaegen. The medical campus and the University Hospital are in Jette.
At VUB and with the financial support of InnoViris, an online histopathology platform was built (on top of Pathomation and Genohm software) that presents a catalogue of tissues available in the biobank. This was done to contribute to the valorization of the biobank, and to lead to new collaborations between academia and industry. The outcome of this project is a hybrid solution that consists of commercial hardware and software, as well as open source packages. This new technology has significantly enhanced research and education activities.
Pathomation was born in November 2012 as a spinoff of the CRO HistoGeneX, which is located in Antwerp (Belgium) and has established a strong reputation in the pharma industry. Back in 2012, no satisfying software solutions were available on the market to establish a fully digitized controlled workflow using digitally scanned glass slides within the HistoGeneX lab. Pathomation was founded to answer these needs.
All Pathomation software was co-developped in close collaboration with the HistoGeneX practicing pathologists, aiming to meet the highest quality standards and user friendliness. Pathomation software is currently up and running within the Histogenex workflow.
About the PMA products platform:
Pathomation has developed a set of software products and tools that can cope with virtually every digital pathology and microscopy scenario imaginable.
Pathomation’s digital microscopy solutions are based on a set of generic components, leading to very versatile products with a very open architecture allowing the highest flexibility possible. The Pathomation products are vendor and format agnostic, avoiding the risk of vendor lock-in, high costs and limited flexibility for future digital pathology applications.
Pathomation has real life experience with digital microscopy and digital pathology in biobanking, pathology labs, research labs, clinical biomarker research, classroom teaching, conference hosting and hosting of trainings for pathologists.
Martijn Devisscher, COO
BRUSSELS FREE UNIVERSITY
Yves Sucaet, PhD